Inmagene Biopharmaceuticals Announces Merger With Ikena Oncology
San Diego – December 23, 2024 – Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA). The transaction is expected to close in mid-2025, subject to customary closing conditions, including approval by each company’s shareholders. Upon completion of the merger, the combined company plans to operate under the name ImageneBio and trade on Nasdaq under the ticker IMA.
Lawyers Lila Hope, Rama Padmanabhan, Patrick Loofbourrow, Asa Henin, Matthew Silverman, Lindsey O’Crump and Brittany Wightman led the Cooley team advising Inmagene.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.